SkyCell closes $116mn Series D, to focus on growth across US, Asia SkyCell transports $2.5bn of pharma goods including vaccines, cancer treatments, diabetes care & diagnostic solutions

SkyCell transports $2.5bn of pharma goods including vaccines, cancer treatments, diabetes care & diagnostic solutions

#SkyCell #TybourneCapitalManagement #CCIndustries #Catalyst #SkyMind #pharma #vaccines #cancertreatments #diabetescare